Production of nitric oxide by hypoxic radiosensitizer sanazole

Experimental Oncology

Volumn 26, Issue 4, 2004, Pages 331-333

  Kondakova, Irina V ^a   Tcheredova, Varvara V ^a   Zagrebelnaya, Gelena V ^a   Cherdyntseva, Nadezda V ^a   Kagiya, Tsutomu V ^b   Choinzonov, Evgeny L ^a  

^a CANCER RESEARCH INSTITUTE   (Russian Federation)

^b HEALTH RESEARCH FOUNDATION   (Japan)

Author keywords

Hypoxic radiosensitizer; Nitric oxide; Sanazole; Tumor cells

Indexed keywords

METHEMOGLOBIN; NITRIC OXIDE; NITRITE; OXYHEMOGLOBIN; PYRROLE DERIVATIVE; RADIOSENSITIZING AGENT; SANAZOLE; UNCLASSIFIED DRUG; SENAZOLE; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CANCER CELL CULTURE; CULTURE MEDIUM; DRUG EFFICACY; HYPOXIC CELL; IMMUNOMODULATION; LYMPHOMA CELL; MASTOCYTOMA; MOUSE; NONHUMAN; RADIOSENSITIZATION; SPECTROPHOTOMETRY; SUPERNATANT; ANIMAL; C57BL MOUSE; CELL HYPOXIA; EXPERIMENTAL NEOPLASM; LYMPHOMA; METABOLISM; PATHOLOGY;

ANIMALS; CELL HYPOXIA; LYMPHOMA; MASTOCYTOMA; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; NITRIC OXIDE; OXYHEMOGLOBINS; RADIATION-SENSITIZING AGENTS; TRIAZOLES;

EID: 12744269477     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Berdov BA, Skoropad V Yu, Sylantieva NK. Prospective clinical trial of the AK-2123 as chemical sensitizer for locally-advanced rectal cancer. Sensitiz Newslett 1995; 2: 4-5.
2. Birjanova NH, Toktamysova ZS. Metronidazole and human red blood cells. Med Radiol (Rus) 1989; 6: 43-5.
3. Feelisch M, Noack EA. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanilate cyclase. Eur J Pharmacol 1987; 139: 19-30.
4. Filep BJG, Baron C, Lachance S, Perreault C, Chan SD. Involvement of nitric oxide in target-cell lysis and DNA fragmentation induced by murine natural killer cells. Blood 1996; 87: 51-6.
5. 15N]nitrate in biological fluids. Anal Biochem 1982; 126: 131-8.
6. Hall EJ, Miller R, Astor M, Rini F. The nitroimidazoles as radiosensitizers and cytotoxic agents. Br J Cancer 1978; 37: 120-3.
7. Hay MP, Wilson WR, Moselen JW, Palmer BD, Denny WA. Hypoxia-selective antitumor agents. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitizers. J Med Chem 1994; 37: 381-91.
8. Hentosh P. Induction and repair of DNA damage in γ-irradiated human lymphoblasts: irradiation in the presence and absence of misonidazole. Radiat Res 1988; 115: 436-47.
9. Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, Jhappan C, Higashimoto Y, He P, Linke SP, Quezado MM, Zurer I, Rotter V, Wink D, Hapella E, Harris CC. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci USA 2003; 100: 143-8.
10. Ivai H, Matsuno E, Sasai K, Shibamoto Y, Abe M. Radiosensitizing activity and pharmacokinetics of multiple dose adminisrered KU-2285 in peripheral nerve tissue in mice. Int J Radiat Oncol Biol Phys 1994; 29: 591-4.
11. Konovalova NP, Diatchkovskaya RF, Volkova LM, Kagiya VT. Anti-tumor effect of AK-2123 by ultra low dose daily administration in B-16 melanoma bearing mice. Sensitiz Newslett 1996; 3: 3-8.
12. Lepoivre M, Chenais B, Yapo A, Lemaire G, Thelander L, Tenu JP. Alterations of ribonucleotide reductase activity following induction of the nitrite-generating pathway in adenocarcinoma cells. J Biol Chem 1990; 265: 14143-9.
13. Maragos CM, Wang JM, Hrabie JM, Oppenheim JJ, Keefer LK. Nitric oxide/nucleophile complexes inhibit the in vitro proliferation of A375 melanoma cells via nitric oxide release. Cancer Res 1993; 53: 564-8.
14. Mozart M, Scuderi R, Celsing F, Aguilar-Santelises M. Nitric oxide induced apoptosis in NALM-6, a leukaemia cell line with low cyclin E protein levels. Cell Prolif 2001; 34: 369-78.
15. Murphy ME, Piper HM, Watanabe H, Sies H. Nitric oxide production by cultured aortic endothelial cells in response to thiol depletion and repenishment. J Biol Chem 1991; 266: 19378-83.
16. Osinsky SP, Bubnovskaya LN, Ganusevich II. In vivo termochemosensitizing activity and pathophysiological effects of hypoxic radiosensitizer AK-2123. Exp Oncol 1994; 16: 61-5.
17. Pervin S, Singh R, Chaudhuri G. Nitric oxide-induced cytostasis and cell cycle arrest of human breast cancer cell line (MDA-MB-231): potential role of cycline D1. Proc Natl Acad Sci USA 2001; 98: 3583-8.
18. Shibamoto Y, Sakano K, Kimura R, Nishimoto SI, Ono K, Kagiya T, Abe M. Radiosensitization in vitro and in vivo by 3-nitrotriazoles. Int J Radiat Oncol Biol Phys 1986; 12: 1063-6.
19. Schepetkin IA, Cherdyntseva NV, Kagia VT. Sanazole as substrate of xanthine oxidase and microsomal NADPH/cytochrome P450 reductase. Pathophysiology 2001; 8: 119-27.
20. Tada T, Nakajima T, Onoyama Y, Murayama C, Mori T, Nagasawa H, Hori H, Inayama S. In vivo radiosensitizing effect of nitroimidazole derivative KIN-804. Int J Radiat Oncol Biol Phys 1994; 29: 601-5.
21. Tcherdyntseva NV, Kokorev OV, Konovalova NP, Kagiya VT. Activation of immunocompetent cells by ultra low dose administration of radiosensitizer AK-2123 in healthy mice. Sensitiz Newslett 1997; 4: 6-9.
22. Varghese AJ, Whitmore GF. Binding to cellular macromolecules as a possible mechanism for the cytotoxicity of misonidazole. Cancer Res 1980; 40: 2165-9.
23. Whitmore GF, Gulyas S, Varghese AJ. Sensitizing and toxicity properties of mizonidazole and its derivatives. Br J Cancer 1978; 37: 115-9.
24. Yamamoto T, Bing RJ. Nitric oxide donors. Proc Soc Exp Biol Med 2000; 225: 200-6.